Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Total Non-Current Liabilities: 2021-2022

Historic Total Non-Current Liabilities for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to $49.7 million.

  • Cardiol Therapeutics' Total Non-Current Liabilities rose 1549.53% to $49.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $49.7 million, marking a year-over-year increase of 1549.53%. This contributed to the annual value of $6.0 million for FY2021, which is N/A change from last year.
  • Per Cardiol Therapeutics' latest filing, its Total Non-Current Liabilities stood at $49.7 million for Q3 2022, which was up 692.40% from -$8.4 million recorded in Q2 2022.
  • Cardiol Therapeutics' 5-year Total Non-Current Liabilities high stood at $75.6 million for Q1 2022, and its period low was -$8.4 million during Q2 2022.
  • In the last 2 years, Cardiol Therapeutics' Total Non-Current Liabilities had a median value of $24.0 million in 2021 and averaged $29.7 million.
  • The largest annual percentage gain for Cardiol Therapeutics' Total Non-Current Liabilities in the last 5 years was 1,549.53% (2022), contrasted with its biggest fall of 396.45% (2022).
  • Cardiol Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $66.4 million in 2021, then skyrocketed by 1,549.53% to $49.7 million in 2022.
  • Its Total Non-Current Liabilities was $49.7 million in Q3 2022, compared to -$8.4 million in Q2 2022 and $75.6 million in Q1 2022.